ADMA Biologics Inc (ADMA)vsModerna Inc (MRNA)
ADMA
ADMA Biologics Inc
$13.19
+0.38%
HEALTHCARE · Cap: $2.93B
MRNA
Moderna Inc
$231.35
-6.97%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 386% more annual revenue ($2.52B vs $519.15M). ADMA leads profitability with a 35.1% profit margin vs -110.5%. ADMA earns a higher WallStSmart Score of 64/100 (C+).
ADMA
Buy64
out of 100
Grade: C+
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+73.1%
Fair Value
$150.76
Current Price
$231.35
$80.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Earnings expanding 46.7% YoY
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
No major concerns identified
Trading at 13.7x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 44.9%.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : ADMA
No major red flags identified for ADMA, but monitor valuation.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ADMA profiles as a mature stock while MRNA is a growth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.17 — expect wider price swings.
MRNA is growing revenue faster at 29.2% — sustainability is the question.
ADMA generates stronger free cash flow (15M), providing more financial flexibility.
Bottom Line
ADMA scores higher overall (64/100 vs 31/100), backed by strong 35.1% margins. MRNA offers better value entry with a 73.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?